Glenmede Trust’s Astera Labs ALAB Stock Holding History

Glenmede Trust’s Portfolio ALAB Stock Details ALAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$486K	Sell	1,007 -902	-47%	-$239K	﹤0.01%	995
2026 Q1	$209K	Buy	1,909 +51	+3%	+$7.26K	﹤0.01%	1289
2025 Q4	$309K	Buy	+1,858	New	+$311K	﹤0.01%	1130

Other funds holding ALAB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Glenmede Trust's ALAB Position: Q2 2026 in Review

Glenmede Trust reduced its Astera Labs (ALAB) stake by 47% in Q2 2026, selling an estimated $239K and leaving 1,007 shares worth $486K. The position accounts for ﹤0.01% of the portfolio, ranked #995.

Glenmede Trust first reported a position in ALAB in Q4 2025 and has held it in 3 quarters since. 989 funds tracked by Wall St. Rank hold ALAB as of Q2 2026.

Glenmede Trust held 1,007 shares of Astera Labs worth $486K as of Q2 2026.
Glenmede Trust sold 902 Astera Labs shares in Q2 2026, an estimated $239K.
Astera Labs made up ﹤0.01% of Glenmede Trust's portfolio in Q2 2026, its #995 holding.
Glenmede Trust first reported a position in Astera Labs in Q4 2025 and has held it in 3 quarters since.
989 funds tracked by Wall St. Rank held Astera Labs as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.